Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...

NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Novo Nordisk and ORA officially seal their partnership to revolutionize obesity care in the Philippines through telehealth.

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...